About half of patients with esophageal cancer presented with stage IV disease; 70.5 percent did not undergo surgical ...

There is a moment, often in films, when the person with cancer finishes chemo and they ring a bell to show that treatment has ...

Pelareorep is also showing strong results in anal cancer, where third-line patients achieved a 29% response rate with responses lasting around 17 months in a setting with no FDA-approved treatments.

Merck & Co., Inc. (NYSE:MRK) Q4 2025 Earnings Call Transcript February 3, 2026 Merck & Co., Inc. beats earnings expectations. Reported EPS is $2.04, expectations were $2.01. Operator: Thank you for ...

DEAR DR. ROACH: I am an 82-year old man who was in good health until I found out that I have an issue in my left kidney. My ...

DelveInsight's Oncolytic Virus Competitive Landscape 2026 report provides comprehensive global coverage of pipeline oncolytic ...

The oncolytic virus therapy landscape has expanded steadily over the past decade, with over 100 companies worldwide pursuing clinical or preclinical programs. A few leaders, such as Candel Therapeutic ...